Xtant Medical Announces the Launch of OsteoFactor Pro™
Xtant Medical Holdings (NYSE: XTNT) has launched OsteoFactor Pro™, an innovative allogeneic growth factor solution designed to enhance bone healing in orthopedic and spine procedures. The product features a biphasic release profile that promotes bone regeneration through targeted angiogenesis, chemotaxis, and osteogenesis.
This ready-to-use solution is compatible with synthetic, allograft, or autograft scaffolds, offering surgeons versatility in bone regeneration approaches. With this launch, Xtant becomes the first vertically integrated company to provide solutions across all five major orthobiologic categories, including demineralized bone matrix, cellular allografts, synthetics, structural allografts, and growth factors.
Xtant Medical Holdings (NYSE: XTNT) ha lanciato OsteoFactor Pro™, una soluzione innovativa a base di fattori di crescita allogenici progettata per migliorare la guarigione ossea nelle procedure ortopediche e spinali. Il prodotto presenta un profilo di rilascio bifasico che favorisce la rigenerazione ossea tramite angiogenesi mirata, chemotassi e osteogenesi.
Questa soluzione pronta all'uso è compatibile con scaffold sintetici, allograft o autograft, offrendo ai chirurghi versatilità negli approcci alla rigenerazione ossea. Con questo lancio, Xtant diventa la prima azienda integrata verticalmente a fornire soluzioni in tutte e cinque le principali categorie di ortobiologici, inclusi matrice ossea demineralizzata, allograft cellulari, sintetici, allograft strutturali e fattori di crescita.
Xtant Medical Holdings (NYSE: XTNT) ha lanzado OsteoFactor Pro™, una innovadora solución de factores de crecimiento alogénicos diseñada para mejorar la cicatrización ósea en procedimientos ortopédicos y de columna. El producto presenta un perfil de liberación bifásico que promueve la regeneración ósea mediante angiogénesis dirigida, quimiotaxis y osteogénesis.
Esta solución lista para usar es compatible con andamios sintéticos, aloinjertos o autoinjertos, ofreciendo a los cirujanos versatilidad en los enfoques de regeneración ósea. Con este lanzamiento, Xtant se convierte en la primera empresa integrada verticalmente que ofrece soluciones en las cinco principales categorías de ortobiología, incluyendo matriz ósea desmineralizada, aloinjertos celulares, sintéticos, aloinjertos estructurales y factores de crecimiento.
Xtant Medical Holdings (NYSE: XTNT)는 정형외과 및 척추 수술에서 골 치유를 향상시키기 위해 설계된 혁신적인 동종 성장 인자 솔루션 OsteoFactor Pro™를 출시했습니다. 이 제품은 혈관 신생, 화학주성 및 골생성을 목표로 하는 이중 단계 방출 프로필을 특징으로 하여 골 재생을 촉진합니다.
즉시 사용 가능한 이 솔루션은 합성, 동종 이식 또는 자가 이식 지지체와 호환되어 외과의사에게 골 재생 접근 방식에서 다양한 선택권을 제공합니다. 이번 출시로 Xtant는 탈광물화 골 기질, 세포 동종 이식편, 합성물, 구조적 동종 이식편, 성장 인자를 포함한 다섯 가지 주요 정형생물학 범주 전반에 걸쳐 솔루션을 제공하는 최초의 수직 통합 기업이 되었습니다.
Xtant Medical Holdings (NYSE: XTNT) a lancé OsteoFactor Pro™, une solution innovante de facteurs de croissance allogéniques conçue pour améliorer la guérison osseuse lors des interventions orthopédiques et rachidiennes. Ce produit présente un profil de libération biphasique qui favorise la régénération osseuse grâce à une angiogenèse ciblée, une chimiotaxie et une ostéogenèse.
Cette solution prête à l'emploi est compatible avec des échafaudages synthétiques, allogreffes ou autogreffes, offrant ainsi aux chirurgiens une grande polyvalence dans les approches de régénération osseuse. Avec ce lancement, Xtant devient la première entreprise intégrée verticalement à proposer des solutions couvrant les cinq principales catégories d'orthobiologie, incluant la matrice osseuse déminéralisée, les allogreffes cellulaires, les synthétiques, les allogreffes structurelles et les facteurs de croissance.
Xtant Medical Holdings (NYSE: XTNT) hat OsteoFactor Pro™ eingeführt, eine innovative allogene Wachstumsfaktorlösung, die die Knochenheilung bei orthopädischen und Wirbelsäulenoperationen verbessern soll. Das Produkt verfügt über ein biphasisches Freisetzungsprofil, das die Knochenregeneration durch gezielte Angiogenese, Chemotaxis und Osteogenese fördert.
Diese gebrauchsfertige Lösung ist mit synthetischen, Allograft- oder Autograft-Gerüsten kompatibel und bietet Chirurgen Flexibilität bei Knochenregenerationsmethoden. Mit dieser Markteinführung wird Xtant das erste vertikal integrierte Unternehmen, das Lösungen in allen fünf großen orthobiologischen Kategorien anbietet, einschließlich demineralisierter Knochenmatrix, zellulärer Allografts, synthetischer Materialien, struktureller Allografts und Wachstumsfaktoren.
- First company to offer solutions across all five major orthobiologic categories, demonstrating market leadership
- Product launch expands company's portfolio and market reach in the orthobiologic sector
- Ready-to-use solution offers versatility and integration with multiple scaffold types
- Nationwide distribution network availability ensures broad market access
- None.
Insights
Xtant's new OsteoFactor Pro significantly expands their orthobiologic portfolio, establishing them as the only fully integrated provider across all five major categories.
Xtant Medical's launch of OsteoFactor Pro™ represents a strategic product expansion that strengthens the company's market position in the orthobiologic space. This allogeneic growth factor solution addresses a critical need in bone regeneration procedures with its biphasic release mechanism—providing both immediate and sustained delivery of growth factors to support the complete healing cascade.
What makes this launch particularly significant is that it completes Xtant's orthobiologic portfolio, making them the first vertically integrated company offering solutions across all five major categories: demineralized bone matrix, cellular allografts, synthetics, structural allografts, and now growth factors. This comprehensive offering creates substantial competitive differentiation in the regenerative medicine market.
The product's versatility is a key advantage—it's designed to complement any orthobiologic scaffold (synthetic, allograft, or autograft), giving surgeons flexibility in their approach to bone regeneration procedures. This adaptability broadens its potential applications across orthopedic and spine surgeries.
From a commercial perspective, the immediate availability through Xtant's nationwide distribution network indicates the company has already established the manufacturing and supply chain infrastructure necessary for a full-scale launch. This suggests potential near-term revenue contribution, though the press release doesn't include specific financial projections or pricing information.
The timing of this launch aligns with growing market demand for advanced biologics that can improve surgical outcomes and potentially reduce revision rates in orthopedic and spine procedures—a significant healthcare cost driver. OsteoFactor Pro's focus on enhancing the body's natural bone regeneration pathways addresses this clinical and economic need.
Allogeneic Growth Factor Solution to Accelerate Bone Repair
OsteoFactor Pro™ is a naturally derived, growth factor-rich formulation that enhances the biologic activity and regenerative potential of any orthobiologic scaffold. Its biphasic release profile—delivering an immediate bolus followed by sustained growth factor release—is designed to drive and stimulate the body's key natural bone regeneration pathways including targeted angiogenesis, chemotaxis, and osteogenesis throughout the healing process.
OsteoFactor Pro™ is an off-the-shelf, ready-to-use solution that integrates seamlessly with synthetic, allograft, or autograft scaffolds. It provides surgeons with exceptional versatility and biologic performance to support a wide range of bone regeneration approaches.
OsteoFactor Pro™ is now available to Xtant Medical's nationwide distribution network.
"This product reflects our commitment to advancing the science of healing through biologics that offer precision, flexibility, and meaningful clinical impact," said Sean Browne, President and CEO of Xtant Medical.
Mark Schallenberger, COO of Xtant Medical added, "With the launch of OsteoFactor Pro™, Xtant becomes the first vertically integrated company to offer solutions across all five major orthobiologic categories—demineralized bone matrix, cellular allografts, synthetics, structural allografts, and now growth factors. This milestone reflects our long-term commitment to innovation, scalability, and meeting the full spectrum of surgeon and patient needs in regenerative medicine."
About Xtant Medical Holdings, Inc.
Xtant Medical's mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.
The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in
Non-GAAP Financial Measures
To supplement the Company's consolidated financial statements prepared in accordance with
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "intends," ''expects,'' ''anticipates,'' ''plans,'' ''believes,'' ''estimates,'' "continue," "future," ''will,'' "potential," "going forward," "guidance," similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Company's full year 2025 revenue guidance and the statement that it expects to begin generating free cash flow in the second half of 2025, enabling the Company to support expected organic growth without the need for additional external capital. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company's future operating results and financial performance; its ability to increase or maintain revenue; the Company's ability to become operationally self-sustaining and less reliant on third-party manufacturers and suppliers; risks associated with its acquisitions and the integration of those businesses; anticipated shortages of stem cells which will adversely affect future revenues; the ability to implement successfully its future growth initiatives and risks associated therewith; possible future impairment charges to long-lived assets and goodwill and write-downs of excess inventory; the ability to remain competitive; the ability to innovate, develop and introduce new products and the success of those products; the ability to engage and retain new and existing independent distributors and agents and qualified personnel and the Company's dependence on key independent agents for a significant portion of its revenue; the effect of labor and hospital staffing shortages on the Company's business, operating results and financial condition, especially when they affect key markets; the effect of inflation, increased interest rates and other recessionary factors and supply chain disruptions; the effect of product sales mix changes on the Company's financial results; government and third-party coverage and reimbursement for Company products; the ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects; the ability to license certain of the Company's intellectual property on commercially reasonable terms and to maintain any such licenses; the ability to obtain and protect Company intellectual property and proprietary rights and operate without infringing the rights of others; risks associated with the Company's clinical trials; international risks; the ability to service Company debt, comply with its debt covenants and access additional indebtedness; the ability to maintain sufficient liquidity to fund its operations and obtain financing on favorable terms or at all; and other factors. Additional risk factors are contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 to be filed with the Securities and Exchange Commission (SEC) on March 6, 2025 and subsequent SEC filings by the Company, including without limitation its most recent Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024 filed with the SEC on November 12, 2024. Investors are encouraged to read the Company's filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.
View original content:https://www.prnewswire.com/news-releases/xtant-medical-announces-the-launch-of-osteofactor-pro-302466283.html
SOURCE Xtant Medical Holdings, Inc.
FAQ
What is Xtant Medical's (XTNT) OsteoFactor Pro and what does it do?
How does OsteoFactor Pro integrate with existing medical procedures?
What makes Xtant Medical (XTNT) unique in the orthobiologic market?
When will OsteoFactor Pro be available for medical use?
